A new trading day began on Monday, with Cardiff Oncology Inc (NASDAQ: CRDF) stock price down -4.46% from the previous day of trading, before settling in for the closing price of $4.26. CRDF’s price has ranged from $1.41 to $6.42 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 9.26% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged -6.21%. With a float of $61.34 million, this company’s outstanding shares have now reached $66.52 million.
In an organization with 32 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 55.01%, operating margin of -6735.99%, and the pretax margin is -6239.04%.
Cardiff Oncology Inc (CRDF) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Cardiff Oncology Inc is 7.79%, while institutional ownership is 27.26%. The most recent insider transaction that took place on Dec 17 ’24, was worth 14,905. In this transaction Chief Financial Officer of this company bought 2,752 shares at a rate of $5.42, taking the stock ownership to the 65,316 shares. Before that another transaction happened on Dec 18 ’24, when Company’s Chief Financial Officer bought 2,400 for $5.00, making the entire transaction worth $12,000. This insider now owns 67,716 shares in total.
Cardiff Oncology Inc (CRDF) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -6.21% per share during the next fiscal year.
Cardiff Oncology Inc (NASDAQ: CRDF) Trading Performance Indicators
Here are Cardiff Oncology Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.74. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 392.36.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.95, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.98 in one year’s time.
Technical Analysis of Cardiff Oncology Inc (CRDF)
Let’s dig in a bit further. During the last 5-days, its volume was 2.98 million. That was better than the volume of 1.22 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 50.19%. Additionally, its Average True Range was 0.51.
During the past 100 days, Cardiff Oncology Inc’s (CRDF) raw stochastic average was set at 56.76%, which indicates a significant increase from 53.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 250.67% in the past 14 days, which was higher than the 126.57% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.11, while its 200-day Moving Average is $3.20. However, in the short run, Cardiff Oncology Inc’s stock first resistance to watch stands at $4.31. Second resistance stands at $4.55. The third major resistance level sits at $4.72. If the price goes on to break the first support level at $3.91, it is likely to go to the next support level at $3.74. The third support level lies at $3.50 if the price breaches the second support level.
Cardiff Oncology Inc (NASDAQ: CRDF) Key Stats
With a market capitalization of 270.73 million, the company has a total of 51,134K Shares Outstanding. Currently, annual sales are 490 K while annual income is -41,440 K. The company’s previous quarter sales were 170 K while its latest quarter income was -11,860 K.
